Journal Mobile Options
Table of Contents
Vol. 4, No. 6, 2004
Issue release date: 2004
Pancreatology 2004;4:561–566

The Role of Extended Resection in Pancreatic Adenocarcinoma: Is There Good Evidence-Based Justification?

Hartel M. · Wente M.N. · Di Sebastiano P. · Friess H. · Büchler M.W.
Department of General Surgery, University of Heidelberg, Heidelberg, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Thus far, there are no studies concerning the radicality of pancreaticoduodenectomy which, in well-performed, randomized-controlled trials employing high standards of evidence-based medicine, show a benefit over extended lymphadenectomy. The results of the only two prospective randomized studies are not comparable and both are underpowered (level of evidence Ib). Therefore, it is still unclear whether extended lymphadenectomy for pancreatic carcinoma improves outcome. Only one study suggests a positive tendency toward increased survival rates in node-positive patients. Extended approaches including additional venous resection can be performed without a rise in the morbidity and mortality rates of patients with pancreatic carcinoma. In the future appropriately powered randomized trials of standard vs. extended resections may show the benefit of extended surgical resections. In addition, well powered trials of postoperative adjuvant therapies or preoperative neoadjuvant strategies together with surgical resections may identify more effective combinations showing a survival benefit in patients with pancreatic carcinoma.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Parkin DM, Pisani P, Ferlay J: Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999;80:827–841.
  2. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ: Cancer statistics, 2003. CA Cancer J Clin 2003;53:5–26.
  3. Delcore R, Rodriguez FJ, Forster J, Hermreck AS, Thomas JH: Significance of lymph node metastases in patients with pancreatic cancer undergoing curative resection. Am J Surg 1996;172:463–468.
  4. Conlon KC, Klimstra DS, Brennan MF: Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 1996;223:273–279.
  5. Geer RJ, Brennan MF: Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993;165:68–72.
  6. Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH, Goodman SN, Dooley WC, Coleman J, Pitt HA: Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995;221:721–731.
  7. Ishikawa O, Ohhigashi H, Sasaki Y, Kabuto T, Fukuda I, Furukawa H, Imaoka S, Iwanaga T: Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head. Ann Surg 1988;208:215–220.
  8. Kayahara M, Nagakawa T, Ueno K, Ohta T, Tsukioka Y, Miyazaki I: Surgical strategy for carcinoma of the pancreas head area based on clinicopathologic analysis of nodal involvement and plexus invasion. Surgery 1995;117:616–623.
  9. Manabe T, Ohshio G, Baba N, Miyashita T, Asano N, Tamura K, Yamaki K, Nonaka A, Tobe T: Radical pancreatectomy for ductal cell carcinoma of the head of the pancreas. Cancer 1989;64:1132–1137.
  10. Satake K, Nishiwaki H, Yokomatsu H, Kawazoe Y, Kim K, Haku A, Umeyama K, Miyazaki I: Surgical curability and prognosis for standard versus extended resection for T1 carcinoma of the pancreas. Surg Gynecol Obstet 1992;175:259–265.
  11. Henne-Bruns D, Vogel I, Luttges J, Kloppel G, Kremer B: Surgery for ductal adenocarcinoma of the pancreatic head: Staging, complications, and survival after regional versus extended lymphadenectomy. World J Surg 2000;24:595–601.
  12. McFadden DW, Reber HA: Cancer of the pancreas: Radical resection-supporting view. Adv Surg 1994;27:257–272.
  13. Fortner JG: Regional resection of cancer of the pancreas: A new surgical approach. Surgery 1973;73:307–320.
  14. Fortner JG, Kim DK, Cubilla A, Turnbull A, Pahnke LD, Shils ME: Regional pancreatectomy: En bloc pancreatic, portal vein and lymph node resection. Ann Surg 1977;186:42–50.
  15. Fortner JG, Klimstra DS, Senie RT, Maclean BJ: Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy. Ann Surg 1996;223:147–153.
  16. Fuhrman GM, Leach SD, Staley CA, Cusack JC, Charnsangavej C, Cleary KR, El Naggar AK, Fenoglio CJ, Lee JE, Evans DB: Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study Group. Ann Surg 1996;223:154–162.
  17. Lillemoe KD, Cameron JL, Yeo CJ, Sohn TA, Nakeeb A, Sauter PK, Hruban RH, Abrams RA, Pitt HA: Pancreaticoduodenectomy. Does it have a role in the palliation of pancreatic cancer? Ann Surg 1996;223:718–725.
  18. Nagakawa T, Mori K, Nakano T, Kadoya M, Kobayashi H, Akiyama T, Kayahara M, Ohta T, Ueno K, Higashino Y: Perineural invasion of carcinoma of the pancreas and biliary tract. Br J Surg 1993;80:619–621.
  19. Birk D, Fortnagel G, Formentini A, Beger HG: Small carcinoma of the pancreas. Factors of prognostic relevance. J Hepatobiliary Pancreat Surg 1998;5:450–454.
  20. Neoptolemos JP, Stocken DD, Dunn JA, Almond J, Beger HG, Pederzoli P, Bassi C, Dervenis C, Fernandez-Cruz L, Lacaine F, Buckels J, Deakin M, Adab FA, Sutton R, Imrie C, Ihse I, Tihanyi T, Olah A, Pedrazzoli S, Spooner D, Kerr DJ, Friess H, Buchler MW: Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001;234:758–768.
  21. Nagakawa T, Nagamori M, Futakami F, Tsukioka Y, Kayahara M, Ohta T, Ueno K, Miyazaki I: Results of extensive surgery for pancreatic carcinoma. Cancer 1996;77:640–645.
  22. Sindelar WF: Clinical experience with regional pancreatectomy for adenocarcinoma of the pancreas. Arch Surg 1989;124:127–132.
  23. Yeo CJ, Cameron JL, Sohn TA, Coleman J, Sauter PK, Hruban RH, Pitt HA, Lillemoe KD: Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma: Comparison of morbidity and mortality and short-term outcome. Ann Surg 1999;229:613–622.
  24. Pedrazzoli S, DiCarlo V, Dionigi R, Mosca F, Pederzoli P, Pasquali C, Kloppel G, Dhaene K, Michelassi F: Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: A multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg 1998;228:508–517.
  25. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Buchler MW: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200–1210.
  26. Yeo CJ, Cameron JL, Lillemoe KD, Sohn TA, Campbell KA, Sauter PK, Coleman J, Abrams RA, Hruban RH: Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma. Part 2: Randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg 2002;236:355–366.
  27. Keck H, Knoop M, Langrehr JM, Henneken V, Neuhaus P: Extended partial Kausch-Whipple duodenopancreatectomy by resection of tumor infiltrated vascular segments (in German). Zentralbl Chir 1995;120:809–814.
  28. Roder JD, Stein HJ, Siewert JR: Carcinoma of the periampullary region: Who benefits from portal vein resection? Am J Surg 1996;171:170–174.
  29. Hartel M, Niedergethmann M, Farag-Soliman M, Sturm JW, Richter A, Trede M, Post S: Benefit of venous resection for ductal adenocarcinoma of the pancreatic head. Eur J Surg 2002;168:707–712.
  30. Harrison LE, Klimstra DS, Brennan MF: Isolated portal vein involvement in pancreatic adenocarcinoma. A contraindication for resection? Ann Surg 1996;224:342–347.
  31. Harrison LE, Brennan MF: Portal vein involvement in pancreatic cancer: A sign of unresectability? Adv Surg 1997;31:375–394.
  32. Klempnauer J, Ridder GJ, Bektas H, Pichlmayr R: Extended resections of ductal pancreatic cancer – Impact on operative risk and prognosis. Oncology 1996;53:47–53.
  33. Nakao A, Harada A, Nonami T, Kaneko T, Inoue S, Takagi H: Clinical significance of portal invasion by pancreatic head carcinoma. Surgery 1995;117:50–55.
  34. Takahashi S, Ogata Y, Tsuzuki T: Combined resection of the pancreas and portal vein for pancreatic cancer. Br J Surg 1994;81:1190–1193.
  35. Shibata C, Kobari M, Tsuchiya T, Arai K, Anzai R, Takahashi M, Uzuki M, Sawai T, Yamazaki T: Pancreatectomy combined with superior mesenteric-portal vein resection for adenocarcinoma in pancreas. World J Surg 2001;25:1002–1005.
  36. van Geenen RC, ten Kate FJ, de Wit LT, van Gulik TM, Obertop H, Gouma DJ: Segmental resection and wedge excision of the portal or superior mesenteric vein during pancreatoduodenectomy. Surgery 2001;129:158–163.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50